Global Human Immumoglobulin (PH4) for Intravenous Injection Supply, Demand and Key Producers, 2026-2032
The global Human Immumoglobulin (PH4) for Intravenous Injection market size is expected to reach $ 22252 million by 2032, rising at a market growth of 8.1% CAGR during the forecast period (2026-2032).
In 2025, global Human Immumoglobulin (PH4) for Intravenous Injection production reached approximately 150.3 tons, with an average global market price of around 83.2 USD/g.
Human Immunoglobulin (PH4) for Intravenous Injection is a sterile blood product derived from pooled plasma of healthy donors, with a pH value maintained at 3.8-4.4 to ensure biological activity. It contains over 95% IgG antibodies, undergoes virus inactivation and removal processes, and serves dual roles of immune replacement and immune regulation. Clinically, it is mainly indicated for primary immunoglobulin deficiencies (e.g., X-linked agammaglobulinemia), secondary deficiencies (e.g., severe infections, neonatal sepsis), and autoimmune diseases (e.g., idiopathic thrombocytopenic purpura, Kawasaki disease). It is a prescription-only biological product requiring strict quality control and regulatory approval.
Driven by aging populations, rising prevalence of autoimmune diseases, expanded clinical indications, and post-pandemic emphasis on immunotherapy, global demand for Human Immunoglobulin (PH4) for Intravenous Injection remains robust, often facing supply shortages due to plasma source constraints. Business opportunities lie in optimizing plasma collection networks to boost raw material supply, advancing production technologies (e.g., nanofiltration, low-pH incubation) for improved yield and safety, developing high-concentration or specialty formulations to meet personalized treatment needs, exploring emerging markets with growing healthcare access, and leveraging policy support for biopharmaceuticals to expand market penetration and enhance product accessibility through pricing and reimbursement strategies.
This report studies the global Human Immumoglobulin (PH4) for Intravenous Injection production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Human Immumoglobulin (PH4) for Intravenous Injection and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Human Immumoglobulin (PH4) for Intravenous Injection that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Human Immumoglobulin (PH4) for Intravenous Injection total production and demand, 2021-2032, (Tons)
Global Human Immumoglobulin (PH4) for Intravenous Injection total production value, 2021-2032, (USD Million)
Global Human Immumoglobulin (PH4) for Intravenous Injection production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Tons), (based on production site)
Global Human Immumoglobulin (PH4) for Intravenous Injection consumption by region & country, CAGR, 2021-2032 & (Tons)
U.S. VS China: Human Immumoglobulin (PH4) for Intravenous Injection domestic production, consumption, key domestic manufacturers and share
Global Human Immumoglobulin (PH4) for Intravenous Injection production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Tons)
Global Human Immumoglobulin (PH4) for Intravenous Injection production by Concentration, production, value, CAGR, 2021-2032, (USD Million) & (Tons)
Global Human Immumoglobulin (PH4) for Intravenous Injection production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Tons)
This report profiles key players in the global Human Immumoglobulin (PH4) for Intravenous Injection market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boya-Bio, Beijing Tiantan Biological Products, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Hualan Bio, CTBB, Sinopharm, Nanyue Biopharming, Shanghai RAAS, ADMA Biologics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Human Immumoglobulin (PH4) for Intravenous Injection market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Tons) and average price (US$/g) by manufacturer, by Concentration, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Human Immumoglobulin (PH4) for Intravenous Injection Market, By Region:
1. How big is the global Human Immumoglobulin (PH4) for Intravenous Injection market?
2. What is the demand of the global Human Immumoglobulin (PH4) for Intravenous Injection market?
3. What is the year over year growth of the global Human Immumoglobulin (PH4) for Intravenous Injection market?
4. What is the production and production value of the global Human Immumoglobulin (PH4) for Intravenous Injection market?
5. Who are the key producers in the global Human Immumoglobulin (PH4) for Intravenous Injection market?
6. What are the growth factors driving the market demand?
In 2025, global Human Immumoglobulin (PH4) for Intravenous Injection production reached approximately 150.3 tons, with an average global market price of around 83.2 USD/g.
Human Immunoglobulin (PH4) for Intravenous Injection is a sterile blood product derived from pooled plasma of healthy donors, with a pH value maintained at 3.8-4.4 to ensure biological activity. It contains over 95% IgG antibodies, undergoes virus inactivation and removal processes, and serves dual roles of immune replacement and immune regulation. Clinically, it is mainly indicated for primary immunoglobulin deficiencies (e.g., X-linked agammaglobulinemia), secondary deficiencies (e.g., severe infections, neonatal sepsis), and autoimmune diseases (e.g., idiopathic thrombocytopenic purpura, Kawasaki disease). It is a prescription-only biological product requiring strict quality control and regulatory approval.
Driven by aging populations, rising prevalence of autoimmune diseases, expanded clinical indications, and post-pandemic emphasis on immunotherapy, global demand for Human Immunoglobulin (PH4) for Intravenous Injection remains robust, often facing supply shortages due to plasma source constraints. Business opportunities lie in optimizing plasma collection networks to boost raw material supply, advancing production technologies (e.g., nanofiltration, low-pH incubation) for improved yield and safety, developing high-concentration or specialty formulations to meet personalized treatment needs, exploring emerging markets with growing healthcare access, and leveraging policy support for biopharmaceuticals to expand market penetration and enhance product accessibility through pricing and reimbursement strategies.
This report studies the global Human Immumoglobulin (PH4) for Intravenous Injection production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Human Immumoglobulin (PH4) for Intravenous Injection and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Human Immumoglobulin (PH4) for Intravenous Injection that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Human Immumoglobulin (PH4) for Intravenous Injection total production and demand, 2021-2032, (Tons)
Global Human Immumoglobulin (PH4) for Intravenous Injection total production value, 2021-2032, (USD Million)
Global Human Immumoglobulin (PH4) for Intravenous Injection production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Tons), (based on production site)
Global Human Immumoglobulin (PH4) for Intravenous Injection consumption by region & country, CAGR, 2021-2032 & (Tons)
U.S. VS China: Human Immumoglobulin (PH4) for Intravenous Injection domestic production, consumption, key domestic manufacturers and share
Global Human Immumoglobulin (PH4) for Intravenous Injection production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Tons)
Global Human Immumoglobulin (PH4) for Intravenous Injection production by Concentration, production, value, CAGR, 2021-2032, (USD Million) & (Tons)
Global Human Immumoglobulin (PH4) for Intravenous Injection production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Tons)
This report profiles key players in the global Human Immumoglobulin (PH4) for Intravenous Injection market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boya-Bio, Beijing Tiantan Biological Products, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Hualan Bio, CTBB, Sinopharm, Nanyue Biopharming, Shanghai RAAS, ADMA Biologics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Human Immumoglobulin (PH4) for Intravenous Injection market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Tons) and average price (US$/g) by manufacturer, by Concentration, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Human Immumoglobulin (PH4) for Intravenous Injection Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- 5%
- 10%
- 20%
- Standard-Qualified Plasma
- High-Safety Plasma
- Special-Indication
- Cohn-Fractionation
- Chromatography-Purified
- Ultrafiltration-Refined
- Immunodeficiency Disease
- Autoimmune Disease
- Severe Infectious Disease
- Boya-Bio
- Beijing Tiantan Biological Products
- Guangdong Shuagnlin Bio-pharmacy
- Weiguang Biological
- Hualan Bio
- CTBB
- Sinopharm
- Nanyue Biopharming
- Shanghai RAAS
- ADMA Biologics
- Grand Shuyang
- PAFC
- Weiguang Biological Products
- Beijing Bohui Innovation Biotechnology
- CSL Behring
- Takeda
- Grifols
- Octapharma
- Bio Products Laboratory
- Kedrion
- LFB
- GC Biopharma
1. How big is the global Human Immumoglobulin (PH4) for Intravenous Injection market?
2. What is the demand of the global Human Immumoglobulin (PH4) for Intravenous Injection market?
3. What is the year over year growth of the global Human Immumoglobulin (PH4) for Intravenous Injection market?
4. What is the production and production value of the global Human Immumoglobulin (PH4) for Intravenous Injection market?
5. Who are the key producers in the global Human Immumoglobulin (PH4) for Intravenous Injection market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Human Immumoglobulin (PH4) for Intravenous Injection Introduction
1.2 World Human Immumoglobulin (PH4) for Intravenous Injection Supply & Forecast
1.2.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021 & 2025 & 2032)
1.2.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.2.3 World Human Immumoglobulin (PH4) for Intravenous Injection Pricing Trends (2021-2032)
1.3 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (Based on Production Site)
1.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2021-2032)
1.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (2021-2032)
1.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2032)
1.3.4 North America Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.5 Europe Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.6 China Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.7 Japan Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.8 Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.9 India Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Human Immumoglobulin (PH4) for Intravenous Injection Major Market Trends
2 DEMAND SUMMARY
2.1 World Human Immumoglobulin (PH4) for Intravenous Injection Demand (2021-2032)
2.2 World Human Immumoglobulin (PH4) for Intravenous Injection Consumption by Region
2.2.1 World Human Immumoglobulin (PH4) for Intravenous Injection Consumption by Region (2021-2026)
2.2.2 World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Forecast by Region (2027-2032)
2.3 United States Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.4 China Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.5 Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.6 Japan Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.7 South Korea Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.8 ASEAN Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.9 India Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Manufacturer (2021-2026)
3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Manufacturer (2021-2026)
3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026)
3.4 Human Immumoglobulin (PH4) for Intravenous Injection Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Human Immumoglobulin (PH4) for Intravenous Injection in 2025
3.5.3 Global Concentration Ratios (CR8) for Human Immumoglobulin (PH4) for Intravenous Injection in 2025
3.6 Human Immumoglobulin (PH4) for Intravenous Injection Market: Overall Company Footprint Analysis
3.6.1 Human Immumoglobulin (PH4) for Intravenous Injection Market: Region Footprint
3.6.2 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint
3.6.3 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Comparison
4.1.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Comparison
4.2.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Comparison
4.3.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021-2026)
4.4.3 United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026)
4.5 China Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers and Market Share
4.5.1 China Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021-2026)
4.5.3 China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026)
4.6 Rest of World Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026)
5 MARKET ANALYSIS BY CONCENTRATION
5.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size Overview by Concentration: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Concentration
5.2.1 5%
5.2.2 10%
5.2.3 20%
5.3 Market Segment by Concentration
5.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Concentration (2021-2032)
5.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration (2021-2032)
5.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032)
6 MARKET ANALYSIS BY SOURCE PLASMA SCREENING STANDARD
6.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size Overview by Source Plasma Screening Standard: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Source Plasma Screening Standard
6.2.1 Standard-Qualified Plasma
6.2.2 High-Safety Plasma
6.2.3 Special-Indication
6.3 Market Segment by Source Plasma Screening Standard
6.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Source Plasma Screening Standard (2021-2032)
6.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard (2021-2032)
6.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2021-2032)
7 MARKET ANALYSIS BY PRODUCTION PROCESS
7.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size Overview by Production Process: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Production Process
7.2.1 Cohn-Fractionation
7.2.2 Chromatography-Purified
7.2.3 Ultrafiltration-Refined
7.3 Market Segment by Production Process
7.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Production Process (2021-2032)
7.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process (2021-2032)
7.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Immunodeficiency Disease
8.2.2 Autoimmune Disease
8.2.3 Severe Infectious Disease
8.3 Market Segment by Application
8.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Application (2021-2032)
8.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application (2021-2032)
8.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Boya-Bio
9.1.1 Boya-Bio Details
9.1.2 Boya-Bio Major Business
9.1.3 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.1.4 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Boya-Bio Recent Developments/Updates
9.1.6 Boya-Bio Competitive Strengths & Weaknesses
9.2 Beijing Tiantan Biological Products
9.2.1 Beijing Tiantan Biological Products Details
9.2.2 Beijing Tiantan Biological Products Major Business
9.2.3 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.2.4 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Beijing Tiantan Biological Products Recent Developments/Updates
9.2.6 Beijing Tiantan Biological Products Competitive Strengths & Weaknesses
9.3 Guangdong Shuagnlin Bio-pharmacy
9.3.1 Guangdong Shuagnlin Bio-pharmacy Details
9.3.2 Guangdong Shuagnlin Bio-pharmacy Major Business
9.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.3.4 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
9.3.6 Guangdong Shuagnlin Bio-pharmacy Competitive Strengths & Weaknesses
9.4 Weiguang Biological
9.4.1 Weiguang Biological Details
9.4.2 Weiguang Biological Major Business
9.4.3 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.4.4 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Weiguang Biological Recent Developments/Updates
9.4.6 Weiguang Biological Competitive Strengths & Weaknesses
9.5 Hualan Bio
9.5.1 Hualan Bio Details
9.5.2 Hualan Bio Major Business
9.5.3 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.5.4 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Hualan Bio Recent Developments/Updates
9.5.6 Hualan Bio Competitive Strengths & Weaknesses
9.6 CTBB
9.6.1 CTBB Details
9.6.2 CTBB Major Business
9.6.3 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.6.4 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 CTBB Recent Developments/Updates
9.6.6 CTBB Competitive Strengths & Weaknesses
9.7 Sinopharm
9.7.1 Sinopharm Details
9.7.2 Sinopharm Major Business
9.7.3 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.7.4 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Sinopharm Recent Developments/Updates
9.7.6 Sinopharm Competitive Strengths & Weaknesses
9.8 Nanyue Biopharming
9.8.1 Nanyue Biopharming Details
9.8.2 Nanyue Biopharming Major Business
9.8.3 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.8.4 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Nanyue Biopharming Recent Developments/Updates
9.8.6 Nanyue Biopharming Competitive Strengths & Weaknesses
9.9 Shanghai RAAS
9.9.1 Shanghai RAAS Details
9.9.2 Shanghai RAAS Major Business
9.9.3 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.9.4 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Shanghai RAAS Recent Developments/Updates
9.9.6 Shanghai RAAS Competitive Strengths & Weaknesses
9.10 ADMA Biologics
9.10.1 ADMA Biologics Details
9.10.2 ADMA Biologics Major Business
9.10.3 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.10.4 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 ADMA Biologics Recent Developments/Updates
9.10.6 ADMA Biologics Competitive Strengths & Weaknesses
9.11 Grand Shuyang
9.11.1 Grand Shuyang Details
9.11.2 Grand Shuyang Major Business
9.11.3 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.11.4 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Grand Shuyang Recent Developments/Updates
9.11.6 Grand Shuyang Competitive Strengths & Weaknesses
9.12 PAFC
9.12.1 PAFC Details
9.12.2 PAFC Major Business
9.12.3 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.12.4 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 PAFC Recent Developments/Updates
9.12.6 PAFC Competitive Strengths & Weaknesses
9.13 Weiguang Biological Products
9.13.1 Weiguang Biological Products Details
9.13.2 Weiguang Biological Products Major Business
9.13.3 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.13.4 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Weiguang Biological Products Recent Developments/Updates
9.13.6 Weiguang Biological Products Competitive Strengths & Weaknesses
9.14 Beijing Bohui Innovation Biotechnology
9.14.1 Beijing Bohui Innovation Biotechnology Details
9.14.2 Beijing Bohui Innovation Biotechnology Major Business
9.14.3 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.14.4 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Beijing Bohui Innovation Biotechnology Recent Developments/Updates
9.14.6 Beijing Bohui Innovation Biotechnology Competitive Strengths & Weaknesses
9.15 CSL Behring
9.15.1 CSL Behring Details
9.15.2 CSL Behring Major Business
9.15.3 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.15.4 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 CSL Behring Recent Developments/Updates
9.15.6 CSL Behring Competitive Strengths & Weaknesses
9.16 Takeda
9.16.1 Takeda Details
9.16.2 Takeda Major Business
9.16.3 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.16.4 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Takeda Recent Developments/Updates
9.16.6 Takeda Competitive Strengths & Weaknesses
9.17 Grifols
9.17.1 Grifols Details
9.17.2 Grifols Major Business
9.17.3 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.17.4 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 Grifols Recent Developments/Updates
9.17.6 Grifols Competitive Strengths & Weaknesses
9.18 Octapharma
9.18.1 Octapharma Details
9.18.2 Octapharma Major Business
9.18.3 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.18.4 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Octapharma Recent Developments/Updates
9.18.6 Octapharma Competitive Strengths & Weaknesses
9.19 Bio Products Laboratory
9.19.1 Bio Products Laboratory Details
9.19.2 Bio Products Laboratory Major Business
9.19.3 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.19.4 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.19.5 Bio Products Laboratory Recent Developments/Updates
9.19.6 Bio Products Laboratory Competitive Strengths & Weaknesses
9.20 Kedrion
9.20.1 Kedrion Details
9.20.2 Kedrion Major Business
9.20.3 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.20.4 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.20.5 Kedrion Recent Developments/Updates
9.20.6 Kedrion Competitive Strengths & Weaknesses
9.21 LFB
9.21.1 LFB Details
9.21.2 LFB Major Business
9.21.3 LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.21.4 LFB Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.21.5 LFB Recent Developments/Updates
9.21.6 LFB Competitive Strengths & Weaknesses
9.22 GC Biopharma
9.22.1 GC Biopharma Details
9.22.2 GC Biopharma Major Business
9.22.3 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.22.4 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.22.5 GC Biopharma Recent Developments/Updates
9.22.6 GC Biopharma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Human Immumoglobulin (PH4) for Intravenous Injection Industry Chain
10.2 Human Immumoglobulin (PH4) for Intravenous Injection Upstream Analysis
10.2.1 Human Immumoglobulin (PH4) for Intravenous Injection Core Raw Materials
10.2.2 Main Manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Human Immumoglobulin (PH4) for Intravenous Injection Production Mode
10.6 Human Immumoglobulin (PH4) for Intravenous Injection Procurement Model
10.7 Human Immumoglobulin (PH4) for Intravenous Injection Industry Sales Model and Sales Channels
10.7.1 Human Immumoglobulin (PH4) for Intravenous Injection Sales Model
10.7.2 Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Human Immumoglobulin (PH4) for Intravenous Injection Introduction
1.2 World Human Immumoglobulin (PH4) for Intravenous Injection Supply & Forecast
1.2.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021 & 2025 & 2032)
1.2.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.2.3 World Human Immumoglobulin (PH4) for Intravenous Injection Pricing Trends (2021-2032)
1.3 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (Based on Production Site)
1.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2021-2032)
1.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (2021-2032)
1.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2032)
1.3.4 North America Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.5 Europe Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.6 China Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.7 Japan Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.8 Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.3.9 India Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Human Immumoglobulin (PH4) for Intravenous Injection Major Market Trends
2 DEMAND SUMMARY
2.1 World Human Immumoglobulin (PH4) for Intravenous Injection Demand (2021-2032)
2.2 World Human Immumoglobulin (PH4) for Intravenous Injection Consumption by Region
2.2.1 World Human Immumoglobulin (PH4) for Intravenous Injection Consumption by Region (2021-2026)
2.2.2 World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Forecast by Region (2027-2032)
2.3 United States Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.4 China Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.5 Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.6 Japan Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.7 South Korea Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.8 ASEAN Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
2.9 India Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Manufacturer (2021-2026)
3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Manufacturer (2021-2026)
3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026)
3.4 Human Immumoglobulin (PH4) for Intravenous Injection Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Human Immumoglobulin (PH4) for Intravenous Injection in 2025
3.5.3 Global Concentration Ratios (CR8) for Human Immumoglobulin (PH4) for Intravenous Injection in 2025
3.6 Human Immumoglobulin (PH4) for Intravenous Injection Market: Overall Company Footprint Analysis
3.6.1 Human Immumoglobulin (PH4) for Intravenous Injection Market: Region Footprint
3.6.2 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint
3.6.3 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Comparison
4.1.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Comparison
4.2.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Comparison
4.3.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021-2026)
4.4.3 United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026)
4.5 China Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers and Market Share
4.5.1 China Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021-2026)
4.5.3 China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026)
4.6 Rest of World Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026)
5 MARKET ANALYSIS BY CONCENTRATION
5.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size Overview by Concentration: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Concentration
5.2.1 5%
5.2.2 10%
5.2.3 20%
5.3 Market Segment by Concentration
5.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Concentration (2021-2032)
5.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration (2021-2032)
5.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032)
6 MARKET ANALYSIS BY SOURCE PLASMA SCREENING STANDARD
6.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size Overview by Source Plasma Screening Standard: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Source Plasma Screening Standard
6.2.1 Standard-Qualified Plasma
6.2.2 High-Safety Plasma
6.2.3 Special-Indication
6.3 Market Segment by Source Plasma Screening Standard
6.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Source Plasma Screening Standard (2021-2032)
6.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard (2021-2032)
6.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2021-2032)
7 MARKET ANALYSIS BY PRODUCTION PROCESS
7.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size Overview by Production Process: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Production Process
7.2.1 Cohn-Fractionation
7.2.2 Chromatography-Purified
7.2.3 Ultrafiltration-Refined
7.3 Market Segment by Production Process
7.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Production Process (2021-2032)
7.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process (2021-2032)
7.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Immunodeficiency Disease
8.2.2 Autoimmune Disease
8.2.3 Severe Infectious Disease
8.3 Market Segment by Application
8.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Application (2021-2032)
8.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application (2021-2032)
8.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Boya-Bio
9.1.1 Boya-Bio Details
9.1.2 Boya-Bio Major Business
9.1.3 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.1.4 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Boya-Bio Recent Developments/Updates
9.1.6 Boya-Bio Competitive Strengths & Weaknesses
9.2 Beijing Tiantan Biological Products
9.2.1 Beijing Tiantan Biological Products Details
9.2.2 Beijing Tiantan Biological Products Major Business
9.2.3 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.2.4 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Beijing Tiantan Biological Products Recent Developments/Updates
9.2.6 Beijing Tiantan Biological Products Competitive Strengths & Weaknesses
9.3 Guangdong Shuagnlin Bio-pharmacy
9.3.1 Guangdong Shuagnlin Bio-pharmacy Details
9.3.2 Guangdong Shuagnlin Bio-pharmacy Major Business
9.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.3.4 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
9.3.6 Guangdong Shuagnlin Bio-pharmacy Competitive Strengths & Weaknesses
9.4 Weiguang Biological
9.4.1 Weiguang Biological Details
9.4.2 Weiguang Biological Major Business
9.4.3 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.4.4 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Weiguang Biological Recent Developments/Updates
9.4.6 Weiguang Biological Competitive Strengths & Weaknesses
9.5 Hualan Bio
9.5.1 Hualan Bio Details
9.5.2 Hualan Bio Major Business
9.5.3 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.5.4 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Hualan Bio Recent Developments/Updates
9.5.6 Hualan Bio Competitive Strengths & Weaknesses
9.6 CTBB
9.6.1 CTBB Details
9.6.2 CTBB Major Business
9.6.3 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.6.4 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 CTBB Recent Developments/Updates
9.6.6 CTBB Competitive Strengths & Weaknesses
9.7 Sinopharm
9.7.1 Sinopharm Details
9.7.2 Sinopharm Major Business
9.7.3 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.7.4 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Sinopharm Recent Developments/Updates
9.7.6 Sinopharm Competitive Strengths & Weaknesses
9.8 Nanyue Biopharming
9.8.1 Nanyue Biopharming Details
9.8.2 Nanyue Biopharming Major Business
9.8.3 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.8.4 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Nanyue Biopharming Recent Developments/Updates
9.8.6 Nanyue Biopharming Competitive Strengths & Weaknesses
9.9 Shanghai RAAS
9.9.1 Shanghai RAAS Details
9.9.2 Shanghai RAAS Major Business
9.9.3 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.9.4 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Shanghai RAAS Recent Developments/Updates
9.9.6 Shanghai RAAS Competitive Strengths & Weaknesses
9.10 ADMA Biologics
9.10.1 ADMA Biologics Details
9.10.2 ADMA Biologics Major Business
9.10.3 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.10.4 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 ADMA Biologics Recent Developments/Updates
9.10.6 ADMA Biologics Competitive Strengths & Weaknesses
9.11 Grand Shuyang
9.11.1 Grand Shuyang Details
9.11.2 Grand Shuyang Major Business
9.11.3 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.11.4 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Grand Shuyang Recent Developments/Updates
9.11.6 Grand Shuyang Competitive Strengths & Weaknesses
9.12 PAFC
9.12.1 PAFC Details
9.12.2 PAFC Major Business
9.12.3 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.12.4 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 PAFC Recent Developments/Updates
9.12.6 PAFC Competitive Strengths & Weaknesses
9.13 Weiguang Biological Products
9.13.1 Weiguang Biological Products Details
9.13.2 Weiguang Biological Products Major Business
9.13.3 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.13.4 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Weiguang Biological Products Recent Developments/Updates
9.13.6 Weiguang Biological Products Competitive Strengths & Weaknesses
9.14 Beijing Bohui Innovation Biotechnology
9.14.1 Beijing Bohui Innovation Biotechnology Details
9.14.2 Beijing Bohui Innovation Biotechnology Major Business
9.14.3 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.14.4 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Beijing Bohui Innovation Biotechnology Recent Developments/Updates
9.14.6 Beijing Bohui Innovation Biotechnology Competitive Strengths & Weaknesses
9.15 CSL Behring
9.15.1 CSL Behring Details
9.15.2 CSL Behring Major Business
9.15.3 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.15.4 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 CSL Behring Recent Developments/Updates
9.15.6 CSL Behring Competitive Strengths & Weaknesses
9.16 Takeda
9.16.1 Takeda Details
9.16.2 Takeda Major Business
9.16.3 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.16.4 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Takeda Recent Developments/Updates
9.16.6 Takeda Competitive Strengths & Weaknesses
9.17 Grifols
9.17.1 Grifols Details
9.17.2 Grifols Major Business
9.17.3 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.17.4 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 Grifols Recent Developments/Updates
9.17.6 Grifols Competitive Strengths & Weaknesses
9.18 Octapharma
9.18.1 Octapharma Details
9.18.2 Octapharma Major Business
9.18.3 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.18.4 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Octapharma Recent Developments/Updates
9.18.6 Octapharma Competitive Strengths & Weaknesses
9.19 Bio Products Laboratory
9.19.1 Bio Products Laboratory Details
9.19.2 Bio Products Laboratory Major Business
9.19.3 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.19.4 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.19.5 Bio Products Laboratory Recent Developments/Updates
9.19.6 Bio Products Laboratory Competitive Strengths & Weaknesses
9.20 Kedrion
9.20.1 Kedrion Details
9.20.2 Kedrion Major Business
9.20.3 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.20.4 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.20.5 Kedrion Recent Developments/Updates
9.20.6 Kedrion Competitive Strengths & Weaknesses
9.21 LFB
9.21.1 LFB Details
9.21.2 LFB Major Business
9.21.3 LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.21.4 LFB Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.21.5 LFB Recent Developments/Updates
9.21.6 LFB Competitive Strengths & Weaknesses
9.22 GC Biopharma
9.22.1 GC Biopharma Details
9.22.2 GC Biopharma Major Business
9.22.3 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
9.22.4 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.22.5 GC Biopharma Recent Developments/Updates
9.22.6 GC Biopharma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Human Immumoglobulin (PH4) for Intravenous Injection Industry Chain
10.2 Human Immumoglobulin (PH4) for Intravenous Injection Upstream Analysis
10.2.1 Human Immumoglobulin (PH4) for Intravenous Injection Core Raw Materials
10.2.2 Main Manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Human Immumoglobulin (PH4) for Intravenous Injection Production Mode
10.6 Human Immumoglobulin (PH4) for Intravenous Injection Procurement Model
10.7 Human Immumoglobulin (PH4) for Intravenous Injection Industry Sales Model and Sales Channels
10.7.1 Human Immumoglobulin (PH4) for Intravenous Injection Sales Model
10.7.2 Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2021-2026) & (USD Million)
Table 3. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2027-2032) & (USD Million)
Table 4. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Region (2021-2026)
Table 5. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Region (2027-2032)
Table 6. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (2021-2026) & (Tons)
Table 7. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (2027-2032) & (Tons)
Table 8. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Region (2021-2026)
Table 9. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Region (2027-2032)
Table 10. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2026) & (US$/g)
Table 11. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2027-2032) & (US$/g)
Table 12. Human Immumoglobulin (PH4) for Intravenous Injection Major Market Trends
Table 13. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (Tons)
Table 14. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption by Region (2021-2026) & (Tons)
Table 15. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Forecast by Region (2027-2032) & (Tons)
Table 16. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Human Immumoglobulin (PH4) for Intravenous Injection Producers in 2025
Table 18. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Manufacturer (2021-2026) & (Tons)
Table 19. Production Market Share of Key Human Immumoglobulin (PH4) for Intravenous Injection Producers in 2025
Table 20. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026) & (US$/g)
Table 21. Global Human Immumoglobulin (PH4) for Intravenous Injection Company Evaluation Quadrant
Table 22. World Human Immumoglobulin (PH4) for Intravenous Injection Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Human Immumoglobulin (PH4) for Intravenous Injection Production Site of Key Manufacturer
Table 24. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint
Table 25. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint
Table 26. Human Immumoglobulin (PH4) for Intravenous Injection Competitive Factors
Table 27. Human Immumoglobulin (PH4) for Intravenous Injection New Entrant and Capacity Expansion Plans
Table 28. Human Immumoglobulin (PH4) for Intravenous Injection Mergers & Acquisitions Activity
Table 29. United States VS China Human Immumoglobulin (PH4) for Intravenous Injection Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Human Immumoglobulin (PH4) for Intravenous Injection Production Comparison, (2021 & 2025 & 2032) & (Tons)
Table 31. United States VS China Human Immumoglobulin (PH4) for Intravenous Injection Consumption Comparison, (2021 & 2025 & 2032) & (Tons)
Table 32. United States Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026) & (Tons)
Table 36. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share (2021-2026)
Table 37. China Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production, (2021-2026) & (Tons)
Table 41. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share (2021-2026)
Table 42. Rest of World Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production, (2021-2026) & (Tons)
Table 46. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share (2021-2026)
Table 47. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration, (USD Million), 2021 & 2025 & 2032
Table 48. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Concentration (2021-2026) & (Tons)
Table 49. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Concentration (2027-2032) & (Tons)
Table 50. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration (2021-2026) & (USD Million)
Table 51. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration (2027-2032) & (USD Million)
Table 52. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2026) & (US$/g)
Table 53. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2027-2032) & (US$/g)
Table 54. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032
Table 55. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Source Plasma Screening Standard (2021-2026) & (Tons)
Table 56. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Source Plasma Screening Standard (2027-2032) & (Tons)
Table 57. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard (2021-2026) & (USD Million)
Table 58. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard (2027-2032) & (USD Million)
Table 59. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2021-2026) & (US$/g)
Table 60. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2027-2032) & (US$/g)
Table 61. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process, (USD Million), 2021 & 2025 & 2032
Table 62. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Production Process (2021-2026) & (Tons)
Table 63. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Production Process (2027-2032) & (Tons)
Table 64. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process (2021-2026) & (USD Million)
Table 65. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process (2027-2032) & (USD Million)
Table 66. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2021-2026) & (US$/g)
Table 67. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2027-2032) & (US$/g)
Table 68. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Application (2021-2026) & (Tons)
Table 70. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Application (2027-2032) & (Tons)
Table 71. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application (2021-2026) & (USD Million)
Table 72. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application (2027-2032) & (USD Million)
Table 73. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2026) & (US$/g)
Table 74. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2027-2032) & (US$/g)
Table 75. Boya-Bio Basic Information, Manufacturing Base and Competitors
Table 76. Boya-Bio Major Business
Table 77. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 78. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Boya-Bio Recent Developments/Updates
Table 80. Boya-Bio Competitive Strengths & Weaknesses
Table 81. Beijing Tiantan Biological Products Basic Information, Manufacturing Base and Competitors
Table 82. Beijing Tiantan Biological Products Major Business
Table 83. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 84. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Beijing Tiantan Biological Products Recent Developments/Updates
Table 86. Beijing Tiantan Biological Products Competitive Strengths & Weaknesses
Table 87. Guangdong Shuagnlin Bio-pharmacy Basic Information, Manufacturing Base and Competitors
Table 88. Guangdong Shuagnlin Bio-pharmacy Major Business
Table 89. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 90. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
Table 92. Guangdong Shuagnlin Bio-pharmacy Competitive Strengths & Weaknesses
Table 93. Weiguang Biological Basic Information, Manufacturing Base and Competitors
Table 94. Weiguang Biological Major Business
Table 95. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 96. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Weiguang Biological Recent Developments/Updates
Table 98. Weiguang Biological Competitive Strengths & Weaknesses
Table 99. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 100. Hualan Bio Major Business
Table 101. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 102. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Hualan Bio Recent Developments/Updates
Table 104. Hualan Bio Competitive Strengths & Weaknesses
Table 105. CTBB Basic Information, Manufacturing Base and Competitors
Table 106. CTBB Major Business
Table 107. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 108. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. CTBB Recent Developments/Updates
Table 110. CTBB Competitive Strengths & Weaknesses
Table 111. Sinopharm Basic Information, Manufacturing Base and Competitors
Table 112. Sinopharm Major Business
Table 113. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 114. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Sinopharm Recent Developments/Updates
Table 116. Sinopharm Competitive Strengths & Weaknesses
Table 117. Nanyue Biopharming Basic Information, Manufacturing Base and Competitors
Table 118. Nanyue Biopharming Major Business
Table 119. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 120. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Nanyue Biopharming Recent Developments/Updates
Table 122. Nanyue Biopharming Competitive Strengths & Weaknesses
Table 123. Shanghai RAAS Basic Information, Manufacturing Base and Competitors
Table 124. Shanghai RAAS Major Business
Table 125. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 126. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Shanghai RAAS Recent Developments/Updates
Table 128. Shanghai RAAS Competitive Strengths & Weaknesses
Table 129. ADMA Biologics Basic Information, Manufacturing Base and Competitors
Table 130. ADMA Biologics Major Business
Table 131. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 132. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. ADMA Biologics Recent Developments/Updates
Table 134. ADMA Biologics Competitive Strengths & Weaknesses
Table 135. Grand Shuyang Basic Information, Manufacturing Base and Competitors
Table 136. Grand Shuyang Major Business
Table 137. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 138. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Grand Shuyang Recent Developments/Updates
Table 140. Grand Shuyang Competitive Strengths & Weaknesses
Table 141. PAFC Basic Information, Manufacturing Base and Competitors
Table 142. PAFC Major Business
Table 143. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 144. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. PAFC Recent Developments/Updates
Table 146. PAFC Competitive Strengths & Weaknesses
Table 147. Weiguang Biological Products Basic Information, Manufacturing Base and Competitors
Table 148. Weiguang Biological Products Major Business
Table 149. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 150. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Weiguang Biological Products Recent Developments/Updates
Table 152. Weiguang Biological Products Competitive Strengths & Weaknesses
Table 153. Beijing Bohui Innovation Biotechnology Basic Information, Manufacturing Base and Competitors
Table 154. Beijing Bohui Innovation Biotechnology Major Business
Table 155. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 156. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Beijing Bohui Innovation Biotechnology Recent Developments/Updates
Table 158. Beijing Bohui Innovation Biotechnology Competitive Strengths & Weaknesses
Table 159. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 160. CSL Behring Major Business
Table 161. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 162. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. CSL Behring Recent Developments/Updates
Table 164. CSL Behring Competitive Strengths & Weaknesses
Table 165. Takeda Basic Information, Manufacturing Base and Competitors
Table 166. Takeda Major Business
Table 167. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 168. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Takeda Recent Developments/Updates
Table 170. Takeda Competitive Strengths & Weaknesses
Table 171. Grifols Basic Information, Manufacturing Base and Competitors
Table 172. Grifols Major Business
Table 173. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 174. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. Grifols Recent Developments/Updates
Table 176. Grifols Competitive Strengths & Weaknesses
Table 177. Octapharma Basic Information, Manufacturing Base and Competitors
Table 178. Octapharma Major Business
Table 179. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 180. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Octapharma Recent Developments/Updates
Table 182. Octapharma Competitive Strengths & Weaknesses
Table 183. Bio Products Laboratory Basic Information, Manufacturing Base and Competitors
Table 184. Bio Products Laboratory Major Business
Table 185. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 186. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 187. Bio Products Laboratory Recent Developments/Updates
Table 188. Bio Products Laboratory Competitive Strengths & Weaknesses
Table 189. Kedrion Basic Information, Manufacturing Base and Competitors
Table 190. Kedrion Major Business
Table 191. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 192. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 193. Kedrion Recent Developments/Updates
Table 194. Kedrion Competitive Strengths & Weaknesses
Table 195. LFB Basic Information, Manufacturing Base and Competitors
Table 196. LFB Major Business
Table 197. LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 198. LFB Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 199. LFB Recent Developments/Updates
Table 200. LFB Competitive Strengths & Weaknesses
Table 201. GC Biopharma Basic Information, Manufacturing Base and Competitors
Table 202. GC Biopharma Major Business
Table 203. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 204. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 205. GC Biopharma Recent Developments/Updates
Table 206. GC Biopharma Competitive Strengths & Weaknesses
Table 207. Global Key Players of Human Immumoglobulin (PH4) for Intravenous Injection Upstream (Raw Materials)
Table 208. Global Human Immumoglobulin (PH4) for Intravenous Injection Typical Customers
Table 209. Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors
Table 1. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2021-2026) & (USD Million)
Table 3. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2027-2032) & (USD Million)
Table 4. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Region (2021-2026)
Table 5. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Region (2027-2032)
Table 6. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (2021-2026) & (Tons)
Table 7. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (2027-2032) & (Tons)
Table 8. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Region (2021-2026)
Table 9. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Region (2027-2032)
Table 10. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2026) & (US$/g)
Table 11. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2027-2032) & (US$/g)
Table 12. Human Immumoglobulin (PH4) for Intravenous Injection Major Market Trends
Table 13. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (Tons)
Table 14. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption by Region (2021-2026) & (Tons)
Table 15. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Forecast by Region (2027-2032) & (Tons)
Table 16. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Human Immumoglobulin (PH4) for Intravenous Injection Producers in 2025
Table 18. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Manufacturer (2021-2026) & (Tons)
Table 19. Production Market Share of Key Human Immumoglobulin (PH4) for Intravenous Injection Producers in 2025
Table 20. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026) & (US$/g)
Table 21. Global Human Immumoglobulin (PH4) for Intravenous Injection Company Evaluation Quadrant
Table 22. World Human Immumoglobulin (PH4) for Intravenous Injection Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Human Immumoglobulin (PH4) for Intravenous Injection Production Site of Key Manufacturer
Table 24. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint
Table 25. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint
Table 26. Human Immumoglobulin (PH4) for Intravenous Injection Competitive Factors
Table 27. Human Immumoglobulin (PH4) for Intravenous Injection New Entrant and Capacity Expansion Plans
Table 28. Human Immumoglobulin (PH4) for Intravenous Injection Mergers & Acquisitions Activity
Table 29. United States VS China Human Immumoglobulin (PH4) for Intravenous Injection Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Human Immumoglobulin (PH4) for Intravenous Injection Production Comparison, (2021 & 2025 & 2032) & (Tons)
Table 31. United States VS China Human Immumoglobulin (PH4) for Intravenous Injection Consumption Comparison, (2021 & 2025 & 2032) & (Tons)
Table 32. United States Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026) & (Tons)
Table 36. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share (2021-2026)
Table 37. China Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production, (2021-2026) & (Tons)
Table 41. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share (2021-2026)
Table 42. Rest of World Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production, (2021-2026) & (Tons)
Table 46. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share (2021-2026)
Table 47. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration, (USD Million), 2021 & 2025 & 2032
Table 48. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Concentration (2021-2026) & (Tons)
Table 49. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Concentration (2027-2032) & (Tons)
Table 50. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration (2021-2026) & (USD Million)
Table 51. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration (2027-2032) & (USD Million)
Table 52. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2026) & (US$/g)
Table 53. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2027-2032) & (US$/g)
Table 54. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032
Table 55. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Source Plasma Screening Standard (2021-2026) & (Tons)
Table 56. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Source Plasma Screening Standard (2027-2032) & (Tons)
Table 57. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard (2021-2026) & (USD Million)
Table 58. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard (2027-2032) & (USD Million)
Table 59. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2021-2026) & (US$/g)
Table 60. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2027-2032) & (US$/g)
Table 61. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process, (USD Million), 2021 & 2025 & 2032
Table 62. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Production Process (2021-2026) & (Tons)
Table 63. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Production Process (2027-2032) & (Tons)
Table 64. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process (2021-2026) & (USD Million)
Table 65. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process (2027-2032) & (USD Million)
Table 66. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2021-2026) & (US$/g)
Table 67. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2027-2032) & (US$/g)
Table 68. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Application (2021-2026) & (Tons)
Table 70. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Application (2027-2032) & (Tons)
Table 71. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application (2021-2026) & (USD Million)
Table 72. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application (2027-2032) & (USD Million)
Table 73. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2026) & (US$/g)
Table 74. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2027-2032) & (US$/g)
Table 75. Boya-Bio Basic Information, Manufacturing Base and Competitors
Table 76. Boya-Bio Major Business
Table 77. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 78. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Boya-Bio Recent Developments/Updates
Table 80. Boya-Bio Competitive Strengths & Weaknesses
Table 81. Beijing Tiantan Biological Products Basic Information, Manufacturing Base and Competitors
Table 82. Beijing Tiantan Biological Products Major Business
Table 83. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 84. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Beijing Tiantan Biological Products Recent Developments/Updates
Table 86. Beijing Tiantan Biological Products Competitive Strengths & Weaknesses
Table 87. Guangdong Shuagnlin Bio-pharmacy Basic Information, Manufacturing Base and Competitors
Table 88. Guangdong Shuagnlin Bio-pharmacy Major Business
Table 89. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 90. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
Table 92. Guangdong Shuagnlin Bio-pharmacy Competitive Strengths & Weaknesses
Table 93. Weiguang Biological Basic Information, Manufacturing Base and Competitors
Table 94. Weiguang Biological Major Business
Table 95. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 96. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Weiguang Biological Recent Developments/Updates
Table 98. Weiguang Biological Competitive Strengths & Weaknesses
Table 99. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 100. Hualan Bio Major Business
Table 101. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 102. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Hualan Bio Recent Developments/Updates
Table 104. Hualan Bio Competitive Strengths & Weaknesses
Table 105. CTBB Basic Information, Manufacturing Base and Competitors
Table 106. CTBB Major Business
Table 107. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 108. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. CTBB Recent Developments/Updates
Table 110. CTBB Competitive Strengths & Weaknesses
Table 111. Sinopharm Basic Information, Manufacturing Base and Competitors
Table 112. Sinopharm Major Business
Table 113. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 114. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Sinopharm Recent Developments/Updates
Table 116. Sinopharm Competitive Strengths & Weaknesses
Table 117. Nanyue Biopharming Basic Information, Manufacturing Base and Competitors
Table 118. Nanyue Biopharming Major Business
Table 119. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 120. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Nanyue Biopharming Recent Developments/Updates
Table 122. Nanyue Biopharming Competitive Strengths & Weaknesses
Table 123. Shanghai RAAS Basic Information, Manufacturing Base and Competitors
Table 124. Shanghai RAAS Major Business
Table 125. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 126. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Shanghai RAAS Recent Developments/Updates
Table 128. Shanghai RAAS Competitive Strengths & Weaknesses
Table 129. ADMA Biologics Basic Information, Manufacturing Base and Competitors
Table 130. ADMA Biologics Major Business
Table 131. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 132. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. ADMA Biologics Recent Developments/Updates
Table 134. ADMA Biologics Competitive Strengths & Weaknesses
Table 135. Grand Shuyang Basic Information, Manufacturing Base and Competitors
Table 136. Grand Shuyang Major Business
Table 137. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 138. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Grand Shuyang Recent Developments/Updates
Table 140. Grand Shuyang Competitive Strengths & Weaknesses
Table 141. PAFC Basic Information, Manufacturing Base and Competitors
Table 142. PAFC Major Business
Table 143. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 144. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. PAFC Recent Developments/Updates
Table 146. PAFC Competitive Strengths & Weaknesses
Table 147. Weiguang Biological Products Basic Information, Manufacturing Base and Competitors
Table 148. Weiguang Biological Products Major Business
Table 149. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 150. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Weiguang Biological Products Recent Developments/Updates
Table 152. Weiguang Biological Products Competitive Strengths & Weaknesses
Table 153. Beijing Bohui Innovation Biotechnology Basic Information, Manufacturing Base and Competitors
Table 154. Beijing Bohui Innovation Biotechnology Major Business
Table 155. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 156. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Beijing Bohui Innovation Biotechnology Recent Developments/Updates
Table 158. Beijing Bohui Innovation Biotechnology Competitive Strengths & Weaknesses
Table 159. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 160. CSL Behring Major Business
Table 161. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 162. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. CSL Behring Recent Developments/Updates
Table 164. CSL Behring Competitive Strengths & Weaknesses
Table 165. Takeda Basic Information, Manufacturing Base and Competitors
Table 166. Takeda Major Business
Table 167. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 168. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Takeda Recent Developments/Updates
Table 170. Takeda Competitive Strengths & Weaknesses
Table 171. Grifols Basic Information, Manufacturing Base and Competitors
Table 172. Grifols Major Business
Table 173. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 174. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. Grifols Recent Developments/Updates
Table 176. Grifols Competitive Strengths & Weaknesses
Table 177. Octapharma Basic Information, Manufacturing Base and Competitors
Table 178. Octapharma Major Business
Table 179. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 180. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Octapharma Recent Developments/Updates
Table 182. Octapharma Competitive Strengths & Weaknesses
Table 183. Bio Products Laboratory Basic Information, Manufacturing Base and Competitors
Table 184. Bio Products Laboratory Major Business
Table 185. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 186. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 187. Bio Products Laboratory Recent Developments/Updates
Table 188. Bio Products Laboratory Competitive Strengths & Weaknesses
Table 189. Kedrion Basic Information, Manufacturing Base and Competitors
Table 190. Kedrion Major Business
Table 191. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 192. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 193. Kedrion Recent Developments/Updates
Table 194. Kedrion Competitive Strengths & Weaknesses
Table 195. LFB Basic Information, Manufacturing Base and Competitors
Table 196. LFB Major Business
Table 197. LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 198. LFB Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 199. LFB Recent Developments/Updates
Table 200. LFB Competitive Strengths & Weaknesses
Table 201. GC Biopharma Basic Information, Manufacturing Base and Competitors
Table 202. GC Biopharma Major Business
Table 203. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 204. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 205. GC Biopharma Recent Developments/Updates
Table 206. GC Biopharma Competitive Strengths & Weaknesses
Table 207. Global Key Players of Human Immumoglobulin (PH4) for Intravenous Injection Upstream (Raw Materials)
Table 208. Global Human Immumoglobulin (PH4) for Intravenous Injection Typical Customers
Table 209. Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors
LIST OF FIGURES
Figure 1. Human Immumoglobulin (PH4) for Intravenous Injection Picture
Figure 2. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 5. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price (2021-2032) & (US$/g)
Figure 6. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Region (2021-2032)
Figure 7. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Region (2021-2032)
Figure 8. North America Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 9. Europe Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 10. China Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 11. Japan Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 12. Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 13. India Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 14. Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
Figure 15. Factors Affecting Demand
Figure 16. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 17. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share by Region (2021-2032)
Figure 18. United States Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 19. China Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 20. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 21. Japan Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 22. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 23. ASEAN Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 24. India Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 25. Producer Shipments of Human Immumoglobulin (PH4) for Intravenous Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 26. Global Four-firm Concentration Ratios (CR4) for Human Immumoglobulin (PH4) for Intravenous Injection Markets in 2025
Figure 27. Global Four-firm Concentration Ratios (CR8) for Human Immumoglobulin (PH4) for Intravenous Injection Markets in 2025
Figure 28. United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 31. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share 2025
Figure 32. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share 2025
Figure 33. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share 2025
Figure 34. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration, (USD Million), 2021 & 2025 & 2032
Figure 35. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Concentration in 2025
Figure 36. 5%
Figure 37. 10%
Figure 38. 20%
Figure 39. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Concentration (2021-2032)
Figure 40. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Concentration (2021-2032)
Figure 41. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032) & (US$/g)
Figure 42. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032
Figure 43. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Source Plasma Screening Standard in 2025
Figure 44. Standard-Qualified Plasma
Figure 45. High-Safety Plasma
Figure 46. Special-Indication
Figure 47. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Source Plasma Screening Standard (2021-2032)
Figure 48. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Source Plasma Screening Standard (2021-2032)
Figure 49. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2021-2032) & (US$/g)
Figure 50. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process, (USD Million), 2021 & 2025 & 2032
Figure 51. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Production Process in 2025
Figure 52. Cohn-Fractionation
Figure 53. Chromatography-Purified
Figure 54. Ultrafiltration-Refined
Figure 55. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Production Process (2021-2032)
Figure 56. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Production Process (2021-2032)
Figure 57. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2021-2032) & (US$/g)
Figure 58. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 59. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Application in 2025
Figure 60. Immunodeficiency Disease
Figure 61. Autoimmune Disease
Figure 62. Severe Infectious Disease
Figure 63. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Application (2021-2032)
Figure 64. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Application (2021-2032)
Figure 65. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032) & (US$/g)
Figure 66. Human Immumoglobulin (PH4) for Intravenous Injection Industry Chain
Figure 67. Human Immumoglobulin (PH4) for Intravenous Injection Procurement Model
Figure 68. Human Immumoglobulin (PH4) for Intravenous Injection Sales Model
Figure 69. Human Immumoglobulin (PH4) for Intravenous Injection Sales Channels, Direct Sales, and Distribution
Figure 70. Methodology
Figure 71. Research Process and Data Source
Figure 1. Human Immumoglobulin (PH4) for Intravenous Injection Picture
Figure 2. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 5. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price (2021-2032) & (US$/g)
Figure 6. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Region (2021-2032)
Figure 7. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Region (2021-2032)
Figure 8. North America Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 9. Europe Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 10. China Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 11. Japan Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 12. Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 13. India Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
Figure 14. Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
Figure 15. Factors Affecting Demand
Figure 16. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 17. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share by Region (2021-2032)
Figure 18. United States Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 19. China Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 20. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 21. Japan Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 22. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 23. ASEAN Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 24. India Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
Figure 25. Producer Shipments of Human Immumoglobulin (PH4) for Intravenous Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 26. Global Four-firm Concentration Ratios (CR4) for Human Immumoglobulin (PH4) for Intravenous Injection Markets in 2025
Figure 27. Global Four-firm Concentration Ratios (CR8) for Human Immumoglobulin (PH4) for Intravenous Injection Markets in 2025
Figure 28. United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 31. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share 2025
Figure 32. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share 2025
Figure 33. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share 2025
Figure 34. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration, (USD Million), 2021 & 2025 & 2032
Figure 35. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Concentration in 2025
Figure 36. 5%
Figure 37. 10%
Figure 38. 20%
Figure 39. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Concentration (2021-2032)
Figure 40. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Concentration (2021-2032)
Figure 41. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032) & (US$/g)
Figure 42. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032
Figure 43. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Source Plasma Screening Standard in 2025
Figure 44. Standard-Qualified Plasma
Figure 45. High-Safety Plasma
Figure 46. Special-Indication
Figure 47. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Source Plasma Screening Standard (2021-2032)
Figure 48. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Source Plasma Screening Standard (2021-2032)
Figure 49. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2021-2032) & (US$/g)
Figure 50. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process, (USD Million), 2021 & 2025 & 2032
Figure 51. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Production Process in 2025
Figure 52. Cohn-Fractionation
Figure 53. Chromatography-Purified
Figure 54. Ultrafiltration-Refined
Figure 55. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Production Process (2021-2032)
Figure 56. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Production Process (2021-2032)
Figure 57. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2021-2032) & (US$/g)
Figure 58. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 59. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Application in 2025
Figure 60. Immunodeficiency Disease
Figure 61. Autoimmune Disease
Figure 62. Severe Infectious Disease
Figure 63. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Application (2021-2032)
Figure 64. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Application (2021-2032)
Figure 65. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032) & (US$/g)
Figure 66. Human Immumoglobulin (PH4) for Intravenous Injection Industry Chain
Figure 67. Human Immumoglobulin (PH4) for Intravenous Injection Procurement Model
Figure 68. Human Immumoglobulin (PH4) for Intravenous Injection Sales Model
Figure 69. Human Immumoglobulin (PH4) for Intravenous Injection Sales Channels, Direct Sales, and Distribution
Figure 70. Methodology
Figure 71. Research Process and Data Source
